Pulmatrix, Inc. (NASDAQ: PULM) is on the move this morning on huge volume


Shares of [finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) are currently up by more than [finviz_code ticker=PULM item=60 value=”35.71%”] from the open today and are trading at $[finviz_code ticker=PULM item=65 value=”3.80″]. More than [finviz_code ticker=PULM item=67 value=”10,042,340″] shares have exchanged hands compared to an average trading volume of [finviz_code ticker=PULM item=63 value=”4.85M”]. At the current pps, the market cap stands at $[finviz_code ticker=PULM item=6 value=”49.57M”]. The stock prices of [finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) are currently trading at [finviz_code ticker=PULM item=57 value=”-45.56%”] below its 52 week high and [finviz_code ticker=PULM item=58 value=”656.97%”] above its 52 week low.

[finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) has been in the news for all the right reasons. Recently, [finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) announced that it has received a key patent from the European Union.

“This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery,” said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases.”

The new EU patent (EP 2410981 B1) follows on similar patents that Pulmatrix has been granted in the United States and Japan. The most important of those patents is US 9,433,576, which gives broad protection to Pulmatrix’s innovative drug delivery technology—and to its use to treat a wide variety of diseases.

The patent extends Pulmatrix’s broad protection for its innovative technology to Europe

[finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) is all set to announce its earnings on [finviz_code ticker=PULM item=68 value=”Mar 31/b”]. As per Zack’s analyst ratings, [finviz_code ticker=PULM item=2 value=”Pulmatrix, Inc.”] (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) currently has an average brokerage rating of [quandl_code ticker=PULM item=ZAR|RATING_MEAN value=””]. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:[finviz_code ticker=PULM item=1 value=”PULM”]) is $[quandl_code ticker=PULM item=ZAR|TP_MEAN_EST value=””] with a high of $[quandl_code ticker=PULM item=ZAR|TP_HIGH_EST value=””] and a low of $[quandl_code ticker=PULM item=ZAR|TP_LOW_EST value=””].

Let’s take a look at the technical analysis.

[intr_chart ticker=PULM src=”http://www.financialstrend.com/wp-content/uploads/2017/03/-PULM4.png”]

[intr_bto ticker=PULM content=”ICAgIFRoZSBCYXJjaGFydCBUZWNobmljYWwgT3BpbmlvbiByYXRpbmcgaXMgYSA2NCUgQnV5IHdpdGggYSBTdHJvbmdlc3Qgc2hvcnQgdGVybSBvdXRsb29rIG9uIG1haW50YWluaW5nIHRoZSBjdXJyZW50IGRpcmVjdGlvbi4gICAgIExvbmdlciB0ZXJtLCB0aGUgdHJlbmQgc3RyZW5ndGggaXMgU3Ryb25nLiAgIExvbmcgdGVybSBpbmRpY2F0b3JzIGZ1bGx5IHN1cHBvcnQgYSBjb250aW51YXRpb24gb2YgdGhlIHRyZW5kLiAgICAgICA=”]

The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). [ema_code ticker=PULM color=red value=2.84|2.96].

The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). [rsi_code ticker=PULM color=red value=42.88]